Oramed terminates HTIT joint venture, repurchases 1.15M shares, reports ~$210M in assets, launches new insulin trial

ORAMED PHARMACEUTICALS INC.

Repurchased 1,155,367 shares from HTIT Biotech at $2.23/share for $2.58M total; shares cancelled.
Terminated joint venture with HTIT after it failed to satisfy closing conditions; oral insulin program to continue independently.
Preliminary unaudited cash and assets ~$210M as of Sep 30, 2025, up from $155.7M in Jan 2023.
Initiating 60-patient US oral insulin trial targeting high-responder subgroups (lower BMI, older) for >1% HbA1c reduction.
Investment portfolio: $27.1M unrealized gain on Alpha Tau ($64.8M position); Scilex loan returned $95.5M of $99.5M.

item 1.01 item 1.02 item 2.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.